Our primary aim was to examine and compare plasma NfL and GFAP levels in the pre-diagnostic phase of multiple neurodegenerative diseases, including Alzheimer’s disease, parkinsonian syndromes, and ALS, investigating their associations with each other and with incident neurodegenerative diseases. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.